Clinical Value of Detection of Soluble Urokinase Receptor and Cystatin C in Urine of Patients with Malignant Tumor

[Objective]To explore the relationship between treatment and the levels of soluble urokinase receptor(suPAR) and Cystatin C in urine of patients with malignant tumor. [Methods]The level of suPAR was measured by ELISA,level of Cystatin C was measured by particles enhance nephelometry immune assay(PENIA),and Dade Behring BNII special protein analysor was applied.82 healthy adults were involved in the control group,and 93 patients with malignant tumor were involved in the case group.The levels of suPAR and Cystatin C in urine of two groups were compared. [Results]The levels of suPAR and Cystatin C in urine of patients with malignant tumor were significantly higher than those of the control group(P0.01). [Conclusion]The levels of suPAR and Cystatin C in urine of patients with malignant tumor were increased significantly compared with those of healthy adults,and it was related to operation of malignant tumor.The detection of suPAR and Cystatin C in urine of patients with malignant tumor may become a new index of diagnosis and prognosis,which has the important clinical value in monitoring and effect judgment in patients with malignant tumor.